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Abstract
Objectives To determine whether searching for Helicobacter pylori and
treating with eradication therapy leads to a reduction in incidence of
gastric cancer among healthy asymptomatic infected individuals.
Design Systematic review and meta-analysis of randomised controlled
trials.
Data sources Medline, Embase, and the Cochrane central register of
controlled trials were searched through to December 2013. Conference
proceedings between 2001 and 2013 were hand searched. A recursive
search was performed with bibliographies of relevant studies. There
were no language restrictions.
Eligibility criteria for selecting studies Randomised controlled trials
examining the effect of at least seven days of eradication therapy on
subsequent occurrence of gastric cancer in adults who tested positive
for Helicobacter pylori but otherwise healthy and asymptomatic were
eligible. The control arm had to receive placebo or no treatment. Subjects
had to be followed for ≥2 years.
Main outcome measures Primary outcome, defined a priori, was the
effect of eradication therapy on the subsequent occurrence of gastric
cancer expressed as a relative risk of gastric cancer with 95% confidence
intervals.
Results The search strategy identified 1560 citations, of which six
individual randomised controlled trials were eligible. Fifty one (1.6%)
gastric cancers occurred among 3294 individuals who received
eradication therapy versus 76 (2.4%) in 3203 control subjects (relative
risk 0.66, 95% confidence interval 0.46 to 0.95), with no heterogeneity
between studies (I2=0%, P=0.60). If the benefit of eradication therapy
was assumed to persist lifelong the number needed to treat was as low
as 15 for Chinese men and as high as 245 for US women.
Conclusions These data provide limited, moderate quality evidence
that searching for and eradicating H pylori reduces the incidence of
gastric cancer in healthy asymptomatic infected Asian individuals, but
these data cannot necessarily be extrapolated to other populations.
Introduction
Gastric cancer is the third commonest cause of cancer death
worldwide, with almost three quarters of a million deaths
annually.1 Despite a declining incidence in many countries in
the developed world, there is an increase in global mortality
from the disease because of population growth and increasing
longevity in developing countries.2
Infection with Helicobacter pylori3 causes chronic gastritis,4
which can lead to gastric atrophy and intestinal metaplasia.
These are the main histological precursors to gastric cancer, and
it is therefore plausible thatH pylori infection may cause gastric
cancer.5 6 A systematic review of nested case-control studies
confirmed that individuals who tested positive forH pyloriwere
between three and six timesmore likely to develop gastric cancer
compared with uninfected controls.7-9 Such data led the
International Agency for Research on Cancer to conclude that
H pyloriwas a class I human carcinogen.10A policy of searching
for and eradicating H pylori among healthy asymptomatic
individuals in populations at high risk of gastric cancer could
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theoretically lead to a reduction in the incidence of gastric
cancer.11 However, healthcare providers have not considered
this policy seriously, and are unlikely to do so until randomised
controlled trials show such a strategy to be effective.
The only fully published systematic review of randomised
controlled trials reported a significant reduction in the relative
risk of developing gastric cancer with H pylori eradication
therapy, comparedwith placebo.12However, the authors included
data from the same trial twice, at two different follow-up
points.13 When data from only one or other of these follow-up
points were included the effect was no longer statistically
significant. Given that it is five years since the publication of
this meta-analysis, the possibility that there may now be more
published trials, as well as longer duration of follow-up in the
existing trials, led us to re-examine this issue. Our hypothesis
was that there may now be a significant effect of H pylori
eradication therapy in preventing gastric cancer in healthy
asymptomatic infected individuals. This is a Cochrane
Collaboration systematic review, with the protocol peer
reviewed, published, and available online.14
Methods
Search strategy and study selection
A search of the medical literature was conducted usingMedline
(1946 to December 2013), Embase (1947 to December 2013),
and the Cochrane central register of controlled trials.
Randomised controlled trials examining the effect of eradication
therapy on subsequent occurrence of gastric cancer in H
pylori-positive adults (>16 years old) who were otherwise
healthy and who were not consulting with gastrointestinal
symptoms were eligible for inclusion (box 1).
The literature search used is detailed in appendix 1 of the
supplementary data. There were no language restrictions, and
abstracts of the papers identified by the initial search were
evaluated by the lead reviewer for appropriateness to the study
question. Abstract books of conference proceedings between
2001 and 2013 were hand searched to identify potentially
eligible studies published only in abstract form. Authors of trial
reports published only as abstracts were contacted and asked to
contribute full datasets or completed papers. The bibliographies
of all identified relevant studies were used to perform a recursive
search of the literature. Articles were assessed independently
by two investigators using pre-designed eligibility forms
according to the eligibility criteria, defined prospectively. Any
disagreement between investigators was resolved by consensus.
For fully published studies that randomised healthy,
asymptomatic, H pylori-positive individuals to receive
eradication therapy or either placebo or no treatment, but which
did not report data concerning subsequent occurrence of gastric
cancer, we contacted the first or senior author in order to
maximise our chances of identifying eligible studies. We also
contacted authors of all eligible studies that did report
subsequent occurrence of gastric cancer, in order to obtain data
at the most recent point of follow-up. Finally, where multiple
articles for a single study were found, we contacted the first or
senior author in order to ensure that only data from the latest
publication from each eligible study were extracted.
Outcome assessment
The primary outcome assessed was the effect of H pylori
eradication therapy, compared with placebo or no treatment, on
the subsequent occurrence of gastric cancer. Secondary
outcomes included the effect of eradication therapy on
subsequent occurrence of oesophageal cancer, effect on gastric
cancer related mortality, effect on all cause mortality, and
adverse events arising from eradication therapy.
Data extraction
All data were extracted independently by two investigators as
dichotomous outcomes (presence or absence of gastric cancer).
In addition, the following clinical data were extracted for each
trial: geographical location, country of origin, number of centres,
method used to confirm H pylori infection, type of H pylori
eradication regimen used (including dose and schedule of
individual drugs within it), duration of treatment, eradication
rate, duration of follow-up, subsequent occurrence of
oesophageal cancer, mortality from gastric cancer, mortality
from other causes, and total number of adverse events reported.
As some of the trials we identified performed upper
gastrointestinal endoscopy and obtained gastric biopsy
specimens in all recruited subjects, we were able to obtain the
number of individuals in these trials with pre-neoplastic lesions
at baseline (defined as presence of gastric atrophy, intestinal
metaplasia, or dysplasia).
Data were extracted as a modified intention-to-treat analysis.
In this, we excluded from the analysis individuals found to be
ineligible after randomisation and those who did not receive the
intervention to which they were assigned; also, because of the
relatively rare nature of the outcome of interest, we assumed
that all subjects lost to follow-up had not developed gastric
cancer but kept them in the denominator for the study. This was
particularly important given that the shortest duration of
follow-up in the studies we identified was ≥4 years, and so
numbers of drop-outs were relatively high. We also performed
a complete case analysis, as a sensitivity analysis, where all
participants for whom data were missing or unavailable were
excluded from the analysis altogether.15
We performed a further two sensitivity analyses with missing
data imputed using two assumptions. In the first of these, we
assumed that the incidence of gastric cancer for missing
participants in either trial arms were the same as that observed
in the trial control arms. In the second of these, which was the
worst case scenario, we assumed that the incidences of gastric
cancer for missing participants in theH pylori eradication arms
were the same as that observed in the trial control arms, but
there were no new gastric cancer cases in the control arms
among those with missing data.
Assessment of risk of bias
Risk of bias assessment was performed independently by two
investigators, with disagreements resolved by discussion. Risk
of bias was assessed as described in the Cochrane handbook16
by recording the method used to generate the randomisation
schedule and conceal allocation; whether blinding was
implemented for participants, staff, and outcome assessment;
what proportion of subjects completed follow-up; and whether
there was evidence of selective reporting of outcomes.
Data synthesis and statistical analysis
Data were pooled using a random effects model17 to give amore
conservative estimate of the effect of H pylori eradication
therapy on the subsequent occurrence of gastric cancer, allowing
for any heterogeneity between studies. The impact of eradication
therapy, compared with placebo or no treatment, was expressed
as a relative risk of occurrence of gastric cancer with 95%
confidence intervals. Adverse events data were also summarised
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Box 1: Eligibility criteria for inclusion in study
• Randomised controlled trials
• Healthy asymptomatic adults (>16 years old)
• Presence of H pylori infection confirmed by any of histology, rapid urease testing, culture from antrum or body biopsies obtained at
upper gastrointestinal endoscopy, H pylori serology, or carbon-urea breath testing
• Compared a recognised H pylori eradication regimen* with placebo or no treatment
• Minimum duration of therapy 7 days
• Minimum duration of follow-up 2 years
• Dichotomous assessment of effect on incidence of gastric cancer†
• At least two gastric cancers occurring during follow-up.
*Proton pump inhibitor (PPI) dual therapy (PPI plus either amoxicillin or clarithromycin); PPI triple therapy (PPI plus any
two of the following: amoxicillin, macrolide, 5-nitroimidazole); H2 antihistamine triple therapy (H2 antihistamine plus any
two of the following: amoxicillin, macrolide, 5-nitroimidazole); bismuth triple therapy (bismuth salt and 5-nitroimidazole
with either amoxicillin or tetracycline); bismuth quadruple therapy (as bismuth triple therapy but with the addition of a PPI);
ranitidine bismuth citrate dual therapy (ranitidine bismuth citrate plus either amoxicillin or clarithromycin); ranitidine bismuth
citrate triple therapy (ranitidine bismuth citrate plus any two of the following: amoxicillin, macrolide, 5-nitroimidazole);
clarithromycin monotherapy.
†Defined as any gastric adenocarcinoma, including intestinal (differentiated) or diffuse (undifferentiated) type or without
specified histology).
with relative risks. The number needed to treat, with a 95%
confidence interval, was calculated using the formula:
Number needed to treat=1/(assumed control risk×(1−relative
risk))
where the assumed control risk varies according to the
population studied and the duration of follow-up.We estimated
the assumed control risk from the lifetime risk of gastric cancer
in Japanese, Chinese, US, and UK men and women, published
by the International Agency for Research on Cancer.18 This
assumes that any benefit ofH pylori eradication persists beyond
the duration of follow-up of trials. Amore conservative estimate
of the number needed to treat was made from the assumed
control risk derived from the meta-analysis.
Heterogeneity between studies was assessed using both the I2
statistic with a cut off of ≥50%, and the χ2 test with a P value
<0.10 used to define a significant degree of heterogeneity.19
Where the degree of statistical heterogeneity was greater than
this between trial results, possible explanations were investigated
using subgroup analyses according to the eradication regimen
used, geographical location, and risk of bias of included trials.
We compared individual relative risks between these analyses
using the Cochran Q statistic. These were exploratory analyses
only and may explain some of the observed variability, but the
results should be interpreted with caution.
Review Manager version 5.1.4 (RevMan for Windows 2008,
the Nordic Cochrane Centre, Copenhagen, Denmark) and
StatsDirect version 2.7.7 (StatsDirect, Sale, Cheshire, England)
were used to generate Forest plots of pooled relative risks for
primary and secondary outcomeswith 95% confidence intervals,
as well as funnel plots. The latter were assessed for evidence
of asymmetry and therefore possible publication bias or other
small study effects, using the Egger test20 if there were ≥10
eligible studies included in the meta-analysis, in line with recent
recommendations.21
Results
The search strategy identified 1560 citations. The titles and
abstracts were reviewed, and 32 articles that were thought to be
potentially eligible for inclusion were retrieved and evaluated
(fig 1⇓). Of these, six individual randomised controlled trials,
reported in 14 separate publications,22-35 compared H pylori
eradication therapy with placebo or no treatment and provided
data on subsequent occurrence of gastric cancer, and therefore
appeared to be eligible. However, five of these were redundant
publications with no new information reported and were
therefore also excluded,29-31 33 34 leaving nine publications from
the six trials that reported extractable unique data.22-28 32 35
Of the remaining 18 articles we identified, six were not
randomised controlled trials,36-41 three were trials comparing the
interventions of interest but did not report any gastric cancer
data,42-44 and two were trials with insufficient incident gastric
cancers occurring during follow-up to meet our inclusion
criteria.45 46 In the latter five studies, the reason for exclusion
was confirmed after contact with the authors. In addition, four
articles were duplicate publications of articles already classed
as ineligible.47-50 Two studies were trials conducted among
patients undergoing endoscopic mucosal resection of early
gastric cancer51 52 rather than healthy asymptomatic infected
subjects, and one did not compare the interventions of interest.53
Table 1⇓ lists the characteristics of eligible and included studies,
including demographic data of participants, methods used to
ascertain gastric cancer incidence, andH pylori eradication rates
(reported using a true intention-to-treat analysis with all
drop-outs assumed to have failed eradication therapy). Three
of the trials, reported in five separate publications, were of
factorial design with some participants also randomised to
receive vitamins, antioxidants, or celecoxib (appendix 2 of the
supplementary data).22 25 26 32 35 The majority of trials were
conducted in Japan or China, with only one study being
conducted outside this region, among a population at high risk
of gastric cancer in Colombia.22 35 The longest duration of
follow-up in the studies we identified was 14.7 years,26 and the
shortest duration was ≥4 years.23 Three trials were at low risk
of bias,24-26 32 one trial was at unclear risk,23 and two trials were
at high risk of bias. Of the two trials at high risk of bias, one
was because there was no placebo comparator for the active
eradication therapy, so that this part of the trial was
unblinded22 35; and the other was due to inconsistencies in data
reporting at the two points of follow-up, with 10 gastric cancers
reported at five years, compared with nine at 10 years.27 28 In
the case of this latter trial, we used data from the 10 year
follow-up in our primary analysis, but substituted the five year
data in a sensitivity analysis.
Effect of H pylori eradication therapy on
subsequent occurrence of gastric cancer
When data were pooled from the six trials at the last point of
follow-up in our primary analysis (including all arms in the two
trials of factorial design that also contained vitamins and
antioxidants22 26 32 35 and the 10 year follow-up data from Zhou27),
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51 (1.6%) gastric cancers had occurred among 3294 healthy
asymptomatic infected subjects who received H pylori
eradication therapy compared with 76 (2.4%) cancers in 3203
individuals allocated to placebo or no treatment. There was only
one case of gastric MALT lymphoma reported in the six
studies,23 but this was not included in the analyses. The relative
risk of subsequent occurrence of gastric cancer with eradication
therapy versus placebo or no treatment was 0.66 (95%
confidence interval 0.46 to 0.95) (fig 2⇓), with no heterogeneity
between studies (I2=0%, P=0.60). There were insufficient trials
to assess for evidence of funnel plot asymmetry. The number
needed to treat, using data from the meta-analysis with an
assumed control risk of 2.4%, was 124 (95% confidence interval
78 to 843). However, if we assume that the benefit of H pylori
eradication persists lifelong, then the number needed to treat is
as low as 15 for Chinese men and as high as 245 for US women
(table 2⇓).
We performed several sensitivity analyses when pooling data
from these six trials (table 3⇓). None of these analyses changed
the statistical significance of the relative risk of subsequent
gastric cancer with eradication therapy compared with placebo
or no treatment, there was no heterogeneity between studies in
any of these analyses, and in most cases the effect sizes were
almost identical. We also performed pre-specified subgroup
analyses (table 4⇓). Importantly, when only Asian studies or
those at low risk of bias were included in the analysis the relative
risk remained statistically significant, with no heterogeneity
between studies in either of these analyses.
We performed further analyses according to the presence or
absence of pre-neoplastic lesions at baseline, and according to
co-administration of antioxidants and vitamins. There was no
significant benefit ofH pylori eradication therapy in preventing
subsequent occurrence of gastric cancer when only those either
with or without pre-neoplastic lesions at baseline were
considered in the analysis (fig 3⇓).When only subjects receiving
H pylori eradication therapy were considered in the analysis,
there was no significant reduction in the relative risk of
subsequent gastric cancer (0.82, 95% confidence interval 0.46
to 1.45) (fig 4⇓), with no heterogeneity between studies (I2=13%,
P=0.33). However, when those receiving eradication therapy
in combination with antioxidants or vitamins were considered
in the analysis the relative risk was significantly lower with
eradication therapy (0.52, 0.31 to 0.87).
Effect of H pylori eradication therapy on
subsequent occurrence of oesophageal
cancer
Only one of the studies we identified reported these data.24 There
were two (0.2%) individuals who developed oesophageal cancer
among 817 healthy asymptomatic infected subjects assigned to
eradication therapy, compared with one (0.1%) of 813 allocated
to placebo (P=0.57). All three cases were squamous cell cancers.
Effect of H pylori eradication therapy on
subsequent mortality from gastric cancer
There were three studies, containing 4475 subjects, which
provided data on mortality from gastric cancer.24 26 28 Follow-up
in these three trials ranged from five years to 14.7 years. Overall,
there were 24 deaths (1.1%) from gastric cancer among 2242
healthy asymptomatic infected individuals randomised to
eradication therapy, compared with 36 (1.6%) deaths in 2233
participants allocated to placebo. The relative risk of death from
gastric cancer with eradication therapy compared with placebo
was 0.67 (95% confidence interval 0.40 to 1.11) (fig 5⇓), with
no heterogeneity between studies (I2=0%, P=0.90).
Effect of H pylori eradication therapy on
subsequent all cause mortality
There were four studies that reported all cause mortality among
5253 recruited individuals according to treatment
allocation.22 24-26 Follow-up in these four trials ranged from six
years to 14.7 years. In total, 192 (7.3%) of 2639 healthy
asymptomatic infected subjects receiving eradication therapy
were dead at last point of follow-up, compared with 175 (6.7%)
of 2614 individuals receiving placebo or no treatment. The
relative risk of death from any cause at last point of follow-up
with eradication therapy compared with placebo or no treatment
was 1.09 (0.86 to 1.38) (fig 6⇓), with no heterogeneity between
studies (I2=6%, P=0.36).
Adverse events
Only one of the studies reported individual adverse events data
with eradication therapy compared with placebo or no treatment,
in a separate paper.54 There was no statistically significant
difference in the incidence of adverse events with eradication
therapy, with the exception of skin rash, which occurred in 3.1%
of those receiving eradication therapy compared with 0.1% of
those allocated placebo. Another study mentioned that side
effects were monitored closely and none of any clinical
importance was detected.22
Discussion
Principal findings
This systematic review andmeta-analysis suggests that searching
for and eradicating H pylori infection reduces the subsequent
incidence of gastric cancer in healthy asymptomatic infected
individuals. This observation was robust through most of the
sensitivity analyses we performed. The number needed to treat
varied according to the risk of cancer in the population under
study, but we estimated that it could be as low as 15 in H
pylori-positive men living in a region with a high risk of gastric
cancer, such as China or Japan, compared with almost 250 in
infected women from a low risk region such as the US.
Strengths and limitations of study
Strengths of this study include a contemporaneous and
exhaustive search strategy, allowing us to pool data from over
6000 subjects in our primary analysis. We contacted authors of
all included studies, as well as some excluded studies, in order
to obtain data from the last point of follow-up, as well as to
ensure we had not missed potentially eligible trials, or included
data from the same study at two different points of follow-up.
There are limitations of this study because of characteristics of
the published literature identified. Only three of the trials we
identified were at low risk of bias.24-26 32 In addition, because of
the factorial design of some of the trials, it is difficult to
determine whether the reduction in relative risk of subsequent
gastric cancer was due to H pylori eradication therapy alone.
The beneficial effect seemed to be more pronounced in the two
studies that co-administered antioxidants and vitamins to
participants, but it should be noted that one of these contained
the majority of gastric cancers and had the longest duration of
follow-up. As all but one study was conducted in East Asia, it
is also not possible to assess the effect of searching for and
eradicating H pylori in Western populations. The eradication
regimens used varied considerably between the individual trials,
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although this reflects the fact that several of these studies were
designed before the widespread adoption of proton pump
inhibitor triple therapy, which was first described in 199455 as
the gold standard for H pylori eradication. Finally, individual
adverse events data were not reported by many of the trials we
identified, and we were not able to assess the balance of benefits
and harms if searching for and eradicating H pylori infection
were to be adopted in the general population.
Comparison with other studies
In models of the natural course of gastric cancer a chronic
inflammatory response in the gastric mucosa leads to a
superficial gastritis, which progresses on to gastric atrophy, and
ultimately intestinal metaplasia.5 6 Both atrophy and intestinal
metaplasia have been proposed as potential precursor lesions
of gastric cancer, with atypical changes then taking place within
the gastric mucosa, resulting in dysplasia. In support of this
model is a study of individuals from communities in Colombia,
with differing risks of gastric cancer, in which less than a quarter
of individuals from the highest risk region had an entirely normal
gastric mucosa by the age of 25 years.56 One of the trials in this
meta-analysis demonstrated a significant reduction in the risk
of subsequent gastric cancer with eradication therapy only in
those without pre-neoplastic changes at baseline,24 suggesting
that there may be a “point of no return” beyond which cancer
prevention by eradication of H pylori infection is no longer
possible.
Although these data suggest that searching for and eradicating
H pylori may reduce the incidence of gastric cancer in healthy
asymptomatic infected individuals, the 95% confidence intervals
are wide and the result is heavily dependent on one study.26
However, other evidence supports these data. There are two
open label trials that have evaluated the efficacy of H pylori
eradication versus no therapy in preventing further gastric
neoplasia in patients who have had an endoscopic mucosal
resection of gastric cancer.51 52 These studies suggest that H
pylori eradication can reduce the future incidence of a
metachronous cancer.
Further support is provided by a recent observational study from
Matsu Island in Taiwan,57 where an approach of searching for
and eradicating H pylori was adopted in 2004. In the following
four years H pylori prevalence among participants fell from
63% at baseline to less than 14% in 2008, and the five year
average incidence of gastric cancer declined from 40.3/100 000
person years to 30.4, yielding a rate ratio of 0.75 (95%
confidence interval 0.37 to 1.52), at a time when gastric cancer
incidence rates in the rest of Taiwan remained static.
A recent systematic review of cost effectiveness studies
suggested this strategy was cost effective.58 Trials fromWestern
countries demonstrate that searching for and eradicatingHpylori
leads to a reduction in the community incidence of dyspepsia,43 48
as well as the costs of managing the condition.47-49 59 The
potential benefits of adopting such a programme are therefore
attractive. However, despite accumulating evidence, only
guidelines from the Asian-Pacific gastric cancer consensus have
made a clear recommendation with respect to searching for and
eradicating H pylori in populations at high risk of gastric
cancer.60
Conclusions and policy implications
These data provide limited, moderate quality, evidence that
searching for and eradicatingH pylori can reduce the incidence
of gastric cancer in healthy asymptomatic infected individuals.
As the only trial conducted in a non-Asian population failed to
show any benefit of such an approach, these data should not be
extrapolated to populations outside Asia. Given that any
programmes based on such an intervention will involve healthy
subjects, there needs to be greater confidence in the estimate of
effect and more information on any potential harms ofH pylori
eradication before such a strategy can be advocated as a means
of preventing gastric cancer. It seems likely that the benefit of
searching for and eradicatingH pylori in healthy asymptomatic
individuals will outweigh any potential harms, especially in
populations at high risk of gastric cancer. However, results from
further trials in different populations are urgently needed to
extend the evidence base.While there are some trials in progress,
countries that wish to develop public health measures to control
gastric cancer should consider appropriate randomised designs
in implementation (for example, cluster methodologies or
comparisons of early against late adopters) in order to add to
our knowledge.
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Tables
Table 1| Characteristics of randomised controlled trials of H pylori eradication therapy versus placebo in the prevention of gastric cancer
Methodology
Method to
detect gastric
cancer cases
Last
point of
follow-up
Eradication
rate (%)†
H pylori
eradication
therapy
regimen
% with
pre-neoplastic
lesions* at
baseline
Characteristics
of participants
Sample
size (No
receiving H
pylori
Method to
confirm H
pylori
infectionLocationStudy
eradication
therapy)
Method of
randomisation
and
concealment of
allocation
stated.
Unblinded
Histological
examination‡
at 6 years
6 years58.0Bismuth
subsalicylate
262 mg,
amoxicillin
500 mg,
metronidazole
375 mg thrice
daily for 2 weeks
100Mean (range)
age 51.1 (29-69)
years, 46.1%
men
852 (437)Histological
examination‡
2
communities
in Narino
Province,
Colombia
Correa
2000 22
and
Correa
2001 35
Method of
randomisation
and
concealment of
allocation
stated. Double
blind
Histological
examination‡
at 2, 5, 8, and
10 years
Leung: 5
years
Zhou: 10
years
55.6Omeprazole
20 mg,
amoxicillin 1 g,
clarithromycin
500 mg twice
daily for 1 week
33.7Mean (range)
age 52.0 (35-75)
years, 47.8%
men
Leung: 587
(295)
Zhou: 552
(276)
Histological
examination
and rapid
urease
testing‡
11 villages in
Yantai
County,
Shandong
Province,
China
Leung
2004 28
and
Zhou
2008 27
Method of
randomisation
and
concealment of
allocation
stated.
Double-blind
Histological
examination‡
at 7.5 years or,
if diagnosed
before 7.5
years, review
of clinical
7.5 years83.7Omeprazole
20 mg,
co-amoxiclav
750 mg,
metronidazole
400 mg twice
daily for 2 weeks
37.7Mean (range)
age 42.2 (35-65)
years, 54.0%
men
1630 (817)Histological
examination
and rapid
urease
testing‡
7 villages in
Changle
County,
Fujian
Province,
China
Wong
2004 24
records and
pathology
specimens by
three blinded
clinicians
Method of
randomisation,
concealment of
allocation, and
blinding not
stated
Histological
examination‡
at ≥4 years
≥4 years74.4Lansoprazole
30 mg,
amoxicillin 1.5 g,
clarithromycin
400 mg once
daily for 1 week
Not reportedMean age not
reported (range
20-59 years),
proportion men
not reported
692 (379)Not reported145 centres
in Japan
Saito
2005 23
Method of
randomisation
and
concealment of
allocation
stated. Double
blind
Histological
examination‡,
clinical,
laboratory, or
pathological
data
14.7
years
73.2Omeprazole
20 mg and
amoxicillin 1 g
twice daily for 2
weeks
64.0Mean (range)
age 46.8 (35-64)
years, 50.0%
men
2258 (1130)Serological
testing
13 villages in
Linqu
County,
Shandong
Province,
China
You
200632
and Ma
2012 26
Method of
randomisation
and
concealment of
allocation
stated. Double
blind
Histological
examination‡
at 5 years
5 years63.5Omeprazole
20 mg,
amoxicillin 1 g,
clarithromycin
500 mg twice
daily for 1 week
100Mean (range)
age 53.0 (35-64)
years, 46.4%
men
513 (255)13Carbon-urea
breath testing
12 villages in
Linqu
County,
Shandong
Province,
China
Wong
2012 25
*Defined as gastric atrophy, intestinal metaplasia, or dysplasia.
†True intention-to-treat analysis, with all drop-outs assumed to have failed eradication therapy.
‡Examination or testing of gastric biopsies obtained from upper gastrointestinal endoscopy.
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Table 2| Numbers needed to treat to prevent one case of gastric cancer calculated from lifetime risk of gastric cancer in each country18
Number needed to treat (95% CI)Lifetime risk (%)SexCountry
15.1 (9.5 to 102.6)19.5MenChina
23.7 (14.9 to 161.3)12.4Women
15.3 (9.6 to 104.2)19.2MenJapan
23.0 (14.5 to 156.3)12.8Women
163.4 (102.9 to 1111.1)1.8MenUSA
245.1 (154.3 to 1666.7)1.2Women
94.9 (59.7 to 645.2)3.1MenUK
163.4 (102.9 to 1111.1)1.8Women
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Table 3| Sensitivity analyses of randomised controlled trials of H pylori eradication therapy in the prevention of gastric cancer
Relative risk (95%
CI) of gastric
cancer
Subjects who received placebo or no
treatment
Subjects who received eradication
therapy
Total
No of
studiesAnalysis
No (%) who
developed gastric
cancerTotal No
No (%) who
developed gastric
cancerTotal No
0.66 (0.46 to 0.95)76 (2.4)320351 (1.6)32946Primary modified intention-to-treat analysis
0.66 (0.46 to 0.94)76 (2.6)296551 (1.7)30736Complete case analysis
0.69 (0.49 to 0.98)75 (2.3)321953 (1.6)33136Modified intention-to-treat analysis with
Leung 2004 instead of Zhou 2008
0.69 (0.48 to 0.98)75 (2.6)290453 (1.8)30176Complete case analysis with Leung 2004
instead of Zhou 2008
0.69 (0.48 to 0.97)78 (2.3)345954 (1.5)35496Modified intention-to-treat analysis including
the celecoxib arms from Wong 2012
0.66 (0.47 to 0.94)79 (2.5)320353 (1.6)32946Modified intention-to-treat analysis assuming
incidence of gastric cancer for missing
participants in both arms same as that
observed in trial control arms
0.69 (0.48 to 0.98)76 (2.4)320353 (1.6)32946Modified intention-to-treat analysis assuming
incidence of gastric cancer for missing
participants in trial treatment arms same as
that observed in the trial control arms, and
no events in missing participants in trial
control arms
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g3174 doi: 10.1136/bmj.g3174 (Published 20 May 2014) Page 9 of 13
RESEARCH
Table 4| Subgroup analyses of randomised controlled trials of H pylori eradication therapy in the prevention of gastric cancer
Relative risk (95% CI)
of gastric cancer
Subjects who received placebo or no
treatmentSubjects who received eradication therapyTotal No
of
studiesAnalysis
No (%) who developed
gastric cancerTotal No
No (%) who developed
gastric cancerTotal No
Eradication therapy
used:
0.61 (0.31 to 1.24)22 (1.3)166014 (0.8)17274PPI triple therapy
0.68 (0.45 to 1.03)54 (3.5)154337 (2.4)15672Other
Study location:
0.64 (0.45 to 0.92)74 (2.7)278848 (1.7)28575Far East
1.42 (0.24 to 8.48)2 (0.5)4153 (0.7)4371South America
Risk of bias:
0.68 (0.46 to 0.99)64 (2.9)219944 (2.0)22023Low
0.57 (0.21 to 1.51)12 (1.2)10047 (0.6)10923High or unclear
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g3174 doi: 10.1136/bmj.g3174 (Published 20 May 2014) Page 10 of 13
RESEARCH
Figures
Fig 1 Flow diagram of assessment of studies identified in the systematic review
Fig 2 Forest plot of randomised controlled trials of H pylori eradication therapy: effect on subsequent occurrence of gastric
cancer
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Fig 3 Forest plot of randomised controlled trials of H pylori eradication therapy: effect on subsequent occurrence of gastric
cancer according to presence or absence of pre-neoplastic lesions at baseline. (You 200632 and Ma 201226 study had
missing data concerning presence or absence of pre-neoplastic lesions at baseline for 16 individuals, leading to the loss
of one gastric cancer from the analysis)
Fig 4 Forest plot of randomised controlled trials of H pylori eradication therapy: effect on subsequent occurrence of gastric
cancer according to anti-oxidant or vitamin use
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Fig 5 Forest plot of randomised controlled trials of H pylori eradication therapy: effect on subsequent mortality from gastric
cancer
Fig 6 Forest plot of randomised controlled trials of H pylori eradication therapy: effect on subsequent all cause mortality
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